SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Talk to Advisor
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

Aakaar Medical Technologies Ltd (AAKAAR)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: AAKAAR Trading | Small Cap | Aakaar Medical Techn Share Price

BSE Share Price
Not Listed

Aakaar Medical Technologies Ltd (AAKAAR)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: AAKAAR Trading | Small Cap | Aakaar Medical Techn Share Price

BSE Share Price
Not Listed
Key Metrics
Valuation Multiples
Market Cap
₹92 Cr.
Current Price
₹0
52-Week Low / High
₹0 / 0
TTM EPS
₹4.7
TTM Sales
₹67 Cr.
Book Value per Share
₹38.5
P/E Ratio
13.82
Lower than its 5-year historical median
Industry PE
35.7
Price to Book (P/B)
1.68
Lower than its 5-year historical median
Price to Sales (P/S)
1.37
Lower than its 5-year historical median
EV/EBITDA
8.46
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
17.06%
Outperforms industry median
Return on Capital Employed (ROCE)
18.45%
Outperforms industry median
Return on Assets (ROA)
9.85%
Operating Profit Margin
15.4%
Net Profit Margin
9.91%
Gross Profit Margin
13.9%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
8.74%
Operating Profit Growth (1 Year)
Slowing versus 3-year growth rate
5.53%
Net Profit Growth (1 Year)
Slowing versus 3-year growth rate
10.12%
Asset Quality
Promoter Holding
67.05%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹40 Cr.
Equity
₹14.2 Cr.
Face Value
₹10
All Time Low / High
- / -

Aakaar Medical Technologies stock performance

Key Ratios
mw4me loader

Check Before You Invest

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Aakaar Medical Technologies Ltd a good quality company?
Aakaar Medical Technologies Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

View More

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

View More
How does Aakaar Medical Technologies Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Aakaar Medical Technologies Ltd vs industry peers?
Aakaar Medical Technologies Ltd revenue CAGR is 46.79%, compared to the industry median CAGR of 4.99%, indicating faster growth and gaining its market share.
Q.1 Promoter shareholding and pledge status of Aakaar Medical Technologies Ltd?
Promoters hold 67.05% of the Aakaar Medical Technologies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Aakaar Medical Technologies Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
View More

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Aakaar Medical Technologies Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation ⓘ

Mar'22Mar'23Mar'24Mar'25Mar'26TTM
ROCE % ⓘ20.4%25.8%23.3%26.7%18.5%-
Value Creation
Index ⓘ		0.50.80.70.90.3-

Growth Parameters ⓘ
Sales ⓘ19.532.846.161.66767
Sales YoY Gr.-68.4%40.7%33.6%8.7%-
Adj EPS ⓘ1.72.335.74.74.7
YoY Gr.-37.5%28.1%92.6%-17.9%-
BVPS (₹) ⓘ8.410.113.122.338.538.5
Adj Net
Profit ⓘ		1.62.22.85.96.67
Cash Flow from Ops. ⓘ0.5-2.9-8-5.4-8.4-
Debt/CF from Ops. ⓘ7.9-2-1.9-4.2-2.2-

CAGR ⓘ

9 Years 5 Years 3 Years 1 Years
Sales ⓘNANA26.9%8.7%
Adj EPS ⓘNANA26.5%-17.9%
BVPSⓘNANA56.2%72.5%
Share Price - - - -

Key Financial Parameters ⓘ

Mar'22Mar'23Mar'24Mar'25Mar'26TTM
Return on
Equity % ⓘ		202525.533.21712.2
Op. Profit
Mgn % ⓘ		12.31110.815.915.4NAN
Net Profit
Mgn % ⓘ		8.26.76.19.69.99.9
Debt to
Equity ⓘ		0.50.61.210.3-
Working Cap
Days ⓘ		02102242493050
Cash Conv.
Cycle ⓘ		01641851952530

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Sales19.4732.7846.1161.5866.96
Operating Expenses ⓘ + 17.0729.2641.1151.8156.65
Manufacturing Costs0.150.090.750.731.06
Material Costs9.0615.0120.9426.2228.20
Employee Cost 4.797.7310.3612.9014.01
Other Costs ⓘ 3.076.439.0611.9513.37
Operating Profit ⓘ 2.403.5359.7710.31
Operating Profit Margin (%) 12.3%10.8%10.8%15.9%15.4%
Other Income ⓘ + 0.040.090.160.180.80
Exceptional Items ⓘ 00000
Interest ⓘ 0.210.431.141.711.80
Depreciation ⓘ 0.020.090.140.120.13
Profit Before Tax ⓘ 2.203.103.898.119.19
Tax ⓘ 0.590.951.022.082.55
Profit After Tax 1.622.152.876.036.64
PAT Margin (%) 8.3%6.6%6.2%9.8%9.9%
Adjusted EPS (₹)1.72.33.05.84.7
Dividend Payout Ratio (%)34.60%24.40%0%0%0%

Valuation of Aakaar Medical Techn - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26

Equity and Liabilities

Shareholders Fund + 8.039.6612.5323.2654.55
Share Capital ⓘ 0.700.700.7010.4214.17
Reserves ⓘ 7.338.9611.8312.8440.38
Debt +3.825.8715.0622.7418.53
Long Term Debt00000
Short Term Debt3.825.8715.0622.7418.53
Minority Interest00000
Trade Payables1.622.531.823.511.88
Others Liabilities ⓘ 4.344.915.376.264
Total Liabilities ⓘ 17.8022.9734.7755.7778.97

Fixed Assets

Net Fixed Assets ⓘ +0.200.360.280.240.29
Gross Block0.430.470.520.610.75
Accumulated Depreciation0.220.110.240.370.46
CWIP ⓘ 00000.40
Investments ⓘ 00000
Inventories711.2514.1814.5519.75
Trade Receivables5.5710.2316.262837.23
Cash Equivalents 2.270.190.305.5516.24
Others Assets ⓘ 2.770.933.757.425.06
Total Assets ⓘ 17.8022.9734.7755.7778.97

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Cash Flow From Operating Activity ⓘ + 0.48-2.93-8.04-5.41-8.36
PBT ⓘ 2.203.103.898.119.19
Adjustment ⓘ 0.170.831.061.581.29
Changes in Working Capital ⓘ -1.25-5.82-11.73-13.12-16.6
Tax Paid ⓘ -0.64-1.04-1.26-1.99-2.25
Cash Flow From Investing Activity ⓘ + -0.23-0.32-0.04-0.050.05
Capex -0.19-0.26-0.05-0.08-0.58
Net Investments -0.05-0.06-0.010.030.05
Others ⓘ 0.0100.0200.58
Cash Flow From Financing Activity ⓘ + -0.811.178.1910.7118.80
Net Proceeds from Shares ⓘ 0005.2627
Net Proceeds from Borrowing ⓘ 00000
Interest Paid ⓘ -0.18-0.36-0.99-1.58-1.65
Dividend Paid ⓘ -0.56-0.53000
Others ⓘ -0.072.069.187.03-6.55
Net Cash Flow ⓘ -0.55-2.080.115.2510.48

Financial Ratio

PARTICULARSMar'22Mar'23Mar'24Mar'25Mar'26
Ratios
ROE (%)20.1624.3525.8833.7217.06
ROCE (%)20.425.8123.2926.6918.45
Asset Turnover Ratio1.091.611.61.360.99
PAT to CFO Conversion(x)0.3-1.36-2.8-0.9-1.26
Working Capital Days
Receivable Days104.5088104.90131.20177.80
Inventory Days131.20101.60100.7085.2093.50
Payable Days65.1050.4037.9037.1034.90

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aakaar Medical Technologies Ltd FAQs

The current trading price of Aakaar Medical Techn on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Aakaar Medical Techn stood at ₹91.77 Cr

The latest P/E ratio of Aakaar Medical Techn as of 31-Dec-1969 is 13.82.

The latest P/B ratio of Aakaar Medical Techn as of 31-Dec-1969 is 1.68.

The 52-week high of Aakaar Medical Techn is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aakaar Medical Techn is ₹66.96 ( Cr.) .

Past 10 year's financial track record analysis by Moneyworks4me indicates that Aakaar Medical Technologies Ltd is a average quality company.

The key valuation ratios of Aakaar Medical Technologies Ltd's currently when compared to its past seem to suggest it is in the Undervalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Aakaar Medical Technologies Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Aakaar Medical Technologies Ltd

Aakaar Medical Technologies Limited was originally incorporated as ‘Aakaar Medical Technologies Private Limited’, a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated June 20, 2013 issued by the Registrar of Companies, Mumbai. Subsequently, the company was converted into a public limited company pursuant to a resolution passed by its shareholders at an extraordinary general meeting held on July 19, 2024 and a fresh certificate of incorporation dated November 18, 2024 was issued by the Registrar of Companies, Mumbai, recording the change in the name of the company from ‘Aakaar Medical Technologies’ to ‘Aakaar Medical Technologies’.

The company is a medical aesthetic company dealing in a wide range of aesthetics & specialized cosmetic products & devices. Its product range includes both Own brands (domestically manufactured products & internationally manufactured devices) and Imported Brands (distribution of imported brands) from countries such as Korea, Spain, Italy, and Austria. It is established a distinctive presence in the medical aesthetic market by exclusively focusing on business-to-business (B2B) channels for product distribution and sales. It supplies its products & devices primarily to dermatologists, plastic surgeons, aesthetic physicians who then sell these products to their end consumers as well as use certain device consumables as part of their treatments. It derives majority of its revenue from Aesthetic products and will continue to focus on its Aesthetic products pipeline.

Business area of the company

Aakaar Medical Technologies is a medical aesthetic company dealing in a wide range of aesthetics & specialised cosmetic products & devices.

Products of the company

  • Injectables & Contouring products
  • Professional Hair & Skin Care products
  • Professional Skin Care products
  • Aesthetic Device products
  • Home Care for Skin products

Awards, accreditations or recognitions

  • 2024: Excellence in Aesthetic Innovation & Service at Starz of India 2024.
  • 2019: Best New Launched Doctor Prescribed Skin Care Cosmetic Range in India for Tubelite Brand Aakaar at GEA Awards 2019.

History and milestones

  • July 21, 2017: Launched its own brand Balback.
  • April 1, 2018: Entered into a tripartite agreement with ACPL and Croma Pharma GmbH for launch of Saypha filler (earlier known as Princess).
  • December 9, 2017: Launched its own brand Lytec.
  • Ocotber 27, 2022: Launched its own brand Etrelume.
  • August 3, 2023: Launched its own brand Swyada.
  • April 01, 2023: Entered into exclusive agreement in licensing, marketing and distribution with Regenera Activa Worldwide S.L for launch of Regenera ActivaAMT.
  • July 21, 2023: Entered into exclusive agreement in licensing, marketing and distribution with Tesslift Co. Limited.
  • August 6, 2024: Launched its own brand Exoluxe and DRS1512.
  • September 2, 2024: Launched its Own brand Eoluxe.
  • November 18, 2024: Conversion of the Company from a private limited company to a public limited company.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×